Pascal Gelebart Selected Research

Pascal Gelebart Research Topics

12	Neoplasms (Cancer) 01/2018 - 02/2005
5	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 02/2013 - 08/2009
4	Carcinogenesis 02/2013 - 06/2010
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2012 - 01/2010
2	Breast Neoplasms (Breast Cancer) 12/2010 - 07/2010
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2016
1	Lymphoma (Lymphomas) 02/2013
1	Microsatellite Instability 07/2011
1	Carcinoma (Carcinomatosis) 12/2010
1	Hematologic Neoplasms (Hematological Malignancy) 08/2009
1	Cardiomyopathies (Cardiomyopathy) 04/2006
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 04/2006
1	Heart Failure 04/2006
1	Hypertension (High Blood Pressure) 07/2002

7	Proteins (Proteins, Gene)FDA Link 02/2013 - 02/2005
5	Anaplastic Lymphoma KinaseIBA 02/2013 - 08/2009
4	CateninsIBA 02/2013 - 07/2010
3	Biological ProductsIBA 02/2011 - 01/2010
3	ParaffinIBA 12/2010 - 08/2009
2	Dihydroorotate DehydrogenaseIBA 01/2018 - 01/2018
2	Glycogen Synthase Kinase 3 betaIBA 01/2010 - 12/2008
1	Casein Kinases (Casein Kinase)IBA 02/2013
1	OligonucleotidesIBA 01/2013
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2012
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2012
1	Small Interfering RNA (siRNA)IBA 01/2012
1	DNA (Deoxyribonucleic Acid)IBA 07/2011
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 07/2011
1	Metalloproteases (Metalloproteinases)IBA 06/2011
1	Interleukin-22 (IL-22)IBA 02/2011
1	Glycogen Synthase KinasesIBA 12/2010
1	Estrogen ReceptorsIBA 12/2010
1	Tyrosine (L-Tyrosine)FDA Link 06/2010
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 06/2010
1	NucleophosminIBA 06/2010
1	Serine (L-Serine)FDA Link 01/2010
1	InterleukinsIBA 08/2009
1	Messenger RNA (mRNA)IBA 08/2009
1	interleukin-21 (interleukin 21)IBA 08/2009
1	Interleukin-21 ReceptorsIBA 08/2009
1	beta CateninIBA 12/2008
1	Protein Isoforms (Isoforms)IBA 04/2006
1	Adenosine Triphosphatases (ATPase)IBA 04/2006
1	CalcineurinIBA 07/2002
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 07/2002
1	Protein Kinase CIBA 07/2002

2	Therapeutics 01/2018 - 01/2016